2-amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one
本品主成份 Acyclovir 能選擇性作用在受病毒感染的細胞上，
經由病毒所特有的thymidine kinase將 Acyclovir 磷酸化成acyclovir monophosphate，再進一步轉變形成
Acyclovir diphosphate及Acyclovir triphosphate，然後干擾單純疱疹病毒的DNA聚合酶，進一步產生抑制病毒DNA複製的作用。
Absorption
Oral
Bioavailability is 10% to 20%. C max is 0.83 to 1.61 mcg/mL (200 to 800 mg at steady state).
IV
C max is 9.8 mcg/mL (5 mg/kg dose), 22.9 mcg/mL (10 mg/kg).
Topical
Systemic absorption is minimal.
Distribution
9% to 33% protein bound.
IV
CSF concentrations are about 50% of plasma values.
Elimination
The t ½ is 2.5 to 3.3 h. Cl and t ½ are dependent on renal function.
IV
62% to 91% is excreted unchanged in the urine. Cl is 5.1 mL/min/kg.
Special Populations
Renal Function Impairment
Total body Cl and t ½ are dependent on renal function. Dosage adjustment recommended.
Elderly
Increased plasma concentrations. Dosage adjustment may be required.
1.單純性?疹(感染部位在頭頸部、生殖器周圍、嘴唇、口腔、陰部)3日內可使用acyclovir或tromantadine藥膏，每次給予藥量限5公克以內(100/7/1）。
2.口服、注射劑及外用藥膏擇一使用，不得合併使用。
